Loading…
Bliss GVS Pharma (BLISSGVS)₹654.75+4.89%Pharmaceuticals
At the end of the Sep 2026 quarter, Bliss GVS Pharma's shareholders were: promoters 50.09%, FIIs 5.06%, DIIs 9.66%, public 35.19%. Promoter holding is up 15.06 percentage points from 35.03% a quarter earlier. FII holding is down 8.25 percentage points from 13.31% a year earlier. It had 47,937 shareholders.
As of · Company filings (shareholding pattern)
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 34.99% | 34.99% | 34.92% | 34.84% | 35.12% | 35.31% | 35.46% | 35.41% | 35.38% | 35.38% | 35.03% | 50.09% |
| FIIs | 15.39% | 14.78% | 13.28% | 12.17% | 13.55% | 13.22% | 12.69% | 13.31% | 14.58% | 10.49% | 8.11% | 5.06% |
| DIIs | 6.64% | 6.63% | 6.62% | 6.60% | 6.59% | 6.59% | 6.58% | 6.02% | 5.82% | 5.08% | 9.50% | 9.66% |
| Public | 42.98% | 43.60% | 45.18% | 46.39% | 44.74% | 44.88% | 45.27% | 45.26% | 44.22% | 49.05% | 47.36% | 35.19% |
| Number of shareholders | 40,752 | 45,150 | 44,730 | 52,929 | 49,551 | 49,510 | 46,700 | 44,454 | 43,374 | 44,867 | 46,760 | 47,937 |
| Holder | Category | Sep 2026 | Change (pp) |
|---|---|---|---|
| Mates Visa Consultancy Private Limited | Promoter | 47.96% | New |
| Clarus Capital I | DII | 4.97% | +1.47 |
| Investor Education And Protection Fund Authority Ministry Of Corporate Affairs | Public | 2.45% | −0.02 |
| Anupam Rasayan India Limited | Promoter | 2.14% | New |
| 360 One Pipe Fund | DII | 2.00% | +0.83 |
| Coeus Global Opportunities Fund | FII | 1.74% | 0.00 |
| Life Insurance Corporation Of India | DII | 1.54% | −1.73 |
| Gee Bee Securities Private Limited | Public | 1.17% | New |
| Amit Ashok Thawani | Public | 1.05% | New |
| Narsimha Shibroor Kamath | Promoter | Exited | — |
| Gulbarga Trading And Investment Private | Public | Exited | — |
| Arjun Gautam Ashra . | Public | Exited | — |
| Gautam Rasiklal Ashra | Public | Exited | — |
| Vibha Gagan Sharma | Promoter | Exited | — |
| Shruti Vishal Rao | Promoter | Exited | — |
| Arian Investment Limited | FII | Exited | — |
| Mateus Ltd | FII | Exited | — |
| Shibroor Gokuldas Kamath | Promoter | Exited | — |
Promoters held 50.09% of Bliss GVS Pharma at the end of the Sep 2026 quarter, up 14.68 percentage points from 35.41% a year earlier.
In the Sep 2026 quarter, foreign institutional investors (FIIs) held 5.06% (down 3.05 percentage points from 8.11% a quarter earlier) and domestic institutions (DIIs) held 9.66% (up 0.16 percentage points from 9.50% a quarter earlier).
Bliss GVS Pharma had 47,937 shareholders at the end of the Sep 2026 quarter, against 44,454 a year earlier.
Clarus Capital I (DII) held 4.97% at the end of the Sep 2026 quarter, the largest named holding outside the promoter group.